JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258936

Human L3MBTL2 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

L3MBTL2 KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.
1 Images
Sanger Sequencing - Human L3MBTL2 knockout HeLa cell lysate (AB258936)
  • Sanger seq

Unknown

Sanger Sequencing - Human L3MBTL2 knockout HeLa cell lysate (AB258936)

Homozygous : 1 bp insertion in exon 1

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.

Disease

Adenocarcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258936-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human L3MBTL2 knockout HeLa cell lysate", "number":"AB258936-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB258936-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
L3MBTL2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The L3MBTL2 protein also known as Lethal(3)malignant brain tumor-like protein 2 is a chromatin-binding protein involved in transcriptional repression. It has an approximate mass of 88 kDa. L3MBTL2 plays a role in the Polycomb group of proteins which are known for chromatin modification and gene expression regulation. The protein is broadly expressed in various tissues with higher expression noted in the thymus and testis.
Biological function summary

L3MBTL2 contributes to maintaining gene silencing through its interaction with various chromatin-modifying complexes. As part of the PcG repression complex it binds to modified histones particularly those marked by methylation to suppress transcription. This role is important for proper development and cellular differentiation as it ensures genes turn off or on at the right times during cell cycle and differentiation processes.

Pathways

L3MBTL2 plays key roles in pathways controlling gene expression and cell cycle regulation. Through the Polycomb repressive complex it connects to pathways that influence cellular proliferation and differentiation. L3MBTL2 often interacts with proteins such as RING1B and EZH2 in these pathways facilitating the propagation of chromatin-associated silencing marks that help coordinate complex gene expression programs.

L3MBTL2 is linked to certain cancers and developmental disorders due to its role in gene regulation. Misregulation of L3MBTL2 has been observed in hematopoietic malignancies impacting the normal proliferation of blood cells. It shares connections with proteins like BMI1 in the context of these disorders highlighting its relevance in maintaining the balance of gene expression required for cellular homeostasis and preventing oncogenesis.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com